Drug or treatment

Ipilimumab clinical trials

• 58Clinical trials
• 21Countries

Newest trials

All recruiting trials (58)

• SBRT followed by a multi-drug immunotherapy and chemo regimen for locally advanced pancreatic cancer

  This trial tests whether giving SBRT followed by a combination of ipilimumab, sintilimab, nab-paclitaxel, and gemcitabine helps people with locally advanced pancreatic cancer.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07683221

• First-Line Nivolumab plus Ipilimumab in unresectable hepatocellular carcinoma

  This study tests whether the combination of nivolumab and ipilimumab is safe and effective for adults with unresectable liver cancer in real-world care in Japan.

  Recruiting at 2 sites Bristol-Myers Squibb · Minato-ku, Tokyo and 1 other locations · NCT07679061

• Sintilimab with chemotherapy, with or without ipilimumab, for resectable stomach/GEJ cancer

  A randomized trial tests whether adding sintilimab (and possibly ipilimumab) to standard chemotherapy around surgery helps people with resectable stomach or gastroesophageal junction cancer.

  Recruiting Phase 2/3 Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Guangzhou, Guangdong · NCT07643623

• 30-minute cycling immediately before nivolumab and ipilimumab for metastatic melanoma

  This trial will test whether a 30-minute cycling session immediately before nivolumab plus ipilimumab boosts immune activity and improves outcomes for people with metastatic melanoma.

  Recruiting Universitätsklinikum Hamburg-Eppendorf · Hamburg, Free and Hanseatic City of Hamburg · NCT07564570

• Combining two immunotherapies, a bevacizumab biosimilar, and liver-artery chemotherapy to shrink advanced liver cancer for possible surgery

  This treatment will try a combo of two immune drugs (sintilimab and ipilimumab N01), a bevacizumab biosimilar, and hepatic arterial infusion chemotherapy to shrink unresectable intermediate-to-advanced hepatocellular carcinoma so more patients can become eligible for surgery.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07560488

• VSV-IFNβ-NIS plus ipilimumab and nivolumab for advanced or metastatic clear cell renal cell carcinoma

  This trial adds a virus-based therapy (VSV-IFNβ-NIS) to standard immunotherapy (ipilimumab and nivolumab) to see if it helps people with advanced or metastatic clear cell renal cell cancer.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07510334

• Sintilimab + ipilimumab N01 with cetuximab and dabrafenib for MSS BRAF V600E metastatic colorectal cancer

  This trial will test whether combining the immunotherapies sintilimab and ipilimumab N01 with cetuximab and dabrafenib helps people with microsatellite-stable, BRAF V600E metastatic colorectal cancer live longer or have better tumor control.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Beijing, Beijing Municipality and 3 other locations · NCT07506109

• Using ctDNA to decide whether to add ipilimumab for people on nivolumab and relatlimab

  This tests whether using a ctDNA blood test to guide adding ipilimumab for adults with advanced or metastatic melanoma on nivolumab and relatlimab leads to longer progression-free survival.

  Recruiting Phase 2 NYU Langone Health · New York, New York · NCT07504796

• Neoadjuvant immunotherapy for high-risk eye melanoma

  This trial tests whether giving nivolumab and ipilimumab before surgery is safe and feasible for adults with high-risk uveal melanoma.

  Recruiting Phase 1 Herlev Hospital · Herlev, Herlev · NCT07501117

• Y90 liver radiation plus immunotherapy and targeted drug for unresectable liver cancer

  This test will see if adding Y90 liver radiation to nivolumab, ipilimumab, and lenvatinib helps people with unresectable hepatocellular carcinoma live longer and have better tumor responses.

  Recruiting Phase 1/2 West China Hospital · Chengdu, Sichuan · NCT07482059

• Pazopanib added to a multi-drug regimen for kids and young adults with recurrent soft tissue sarcomas

  This study tests whether adding pazopanib to a regimen of trabectedin, ipilimumab, and nivolumab is safe and possibly beneficial for children and young adults with recurrent soft tissue sarcomas.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT07444619

• DNAJB1-PRKACA vaccine plus DRP-104, nivolumab, and ipilimumab for advanced fibrolamellar liver cancer

  A early-stage study tests whether a personalized vaccine plus two immune drugs and a glutamine-blocking agent can safely help people with advanced fibrolamellar liver cancer.

  Recruiting Phase 1 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT07430202

• TACE with sintilimab, bevacizumab, and ipilimumab N01 for advanced liver cancer

  This trial tries a combination of TACE with sintilimab and bevacizumab plus a single dose of ipilimumab N01 given at different times to see if it is safe and helps people with advanced hepatocellular carcinoma whose tumors cannot be removed.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07422753

• Comparing chemo‑immunotherapy options for metastatic NSCLC with PD‑L1 <50%

  This project will see if two common first‑line chemo‑immunotherapy approaches give different survival and quality‑of‑life results for adults with metastatic NSCLC whose tumors have PD‑L1 under 50%.

  Recruiting at 2 sites Gazi University · Ankara and 1 other locations · NCT07394062

• First-Line Ipilimumab, Nivolumab, and IL-15 Superagonist in Advanced or Recurrent NSCLC

  A phase Ib/II study tests whether adding nogapendekin alfa inbakicept to nivolumab and ipilimumab helps people with stage IV or recurrent non-small cell lung cancer.

  Recruiting Phase 1/2 Washington University School of Medicine · St Louis, Missouri · NCT07355205

• Pumitamig alone or with ipilimumab for first-line advanced or unresectable liver cancer

  This trial will test whether pumitamig, alone or combined with ipilimumab, is safe and tolerable for people with advanced or unresectable hepatocellular carcinoma who have not had prior systemic therapy.

  Recruiting at 38 sites Phase 1/2 Bristol-Myers Squibb · Duarte, California and 66 other locations · NCT07291076

• First-line nivolumab plus ipilimumab with short-course chemotherapy for metastatic non-small cell lung cancer

  This project will collect real-world data to see if nivolumab plus ipilimumab combined with a short course of platinum chemotherapy works well as first-line treatment for adults with metastatic non-small cell lung cancer who do not have EGFR or ALK alterations.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia, Lombardy · NCT07190677

• First-line immune-checkpoint antibody combinations for advanced clear cell kidney cancer

  This trial tests whether combining fianlimab and cemiplimab, with or without ipilimumab, works better than the standard ipilimumab plus nivolumab as first treatment for people with advanced clear cell kidney cancer.

  Recruiting at 5 sites Phase 2 Hoosier Cancer Research Network · Washington D.C., District of Columbia and 4 other locations · NCT07188896

• Comparing the ipilimumab biosimilar HLX13 with US-sourced YERVOY® as first-line treatment for unresectable liver cancer

  This study tests whether the ipilimumab biosimilar HLX13 works like US-sourced YERVOY® and is safe for adults with unresectable hepatocellular carcinoma who have not had prior systemic therapy.

  Recruiting at 46 sites Phase 1 Shanghai Henlius Biotech · Glendale, California and 50 other locations · NCT07176650

• Giving immunotherapy before standard treatment for newly diagnosed glioblastoma

  This Phase 1 trial tests whether giving two doses of the immunotherapy drug ipilimumab before surgery is safe and may help people with newly diagnosed glioblastoma or gliosarcoma.

  Recruiting Phase 1 University College, London · London, Greater London · NCT07134842

• Nivolumab and ipilimumab with or without EXL01 for advanced or metastatic clear-cell and sarcomatoid renal cell carcinoma

  This trial tests whether adding EXL01, a live Faecalibacterium prausnitzii product, to nivolumab and ipilimumab helps adults with advanced or metastatic clear-cell or sarcomatoid renal cell cancer.

  Recruiting at 2 sites Phase 1 City of Hope Medical Center · Duarte, California and 1 other locations · NCT07128680

• Ipilimumab and nivolumab plus focused liver radiation for locally advanced liver cancer

  This trial tests whether combining nivolumab and ipilimumab with focused liver radiation (SBRT) can help adults with locally advanced hepatocellular carcinoma, with attention to including Native Hawaiian and Pacific Islander patients.

  Recruiting Phase 1 University of Hawaii · Honolulu, Hawaii and 1 other locations · NCT07075120

• Neoadjuvant ipilimumab, relatlimab, and nivolumab combinations for resectable cutaneous and mucosal melanoma

  This phase 2 trial will test several immunotherapy combinations given before surgery to try to reduce recurrence in adults with resectable stage 3 cutaneous melanoma or resectable mucosal melanoma, including patients predicted or known to respond poorly to standard anti‑PD‑1 therapy.

  Recruiting Phase 2 Melanoma Institute Australia · Wollstonecraft, New South Wales · NCT06999980

• Combination of nivolumab and ipilimumab before surgery for lung cancer

  This study is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, before surgery to see if it helps people with advanced lung cancer do better than traditional treatments.

  Recruiting Phase 2 The First Affiliated Hospital of Guangzhou Medical University · Guangzhou · NCT06926790

• Testing a new treatment for advanced neuroendocrine tumors

  This study is testing a new treatment combining a virus with two cancer drugs to see if it helps people with advanced neuroendocrine tumors feel better and tolerate the treatment well.

  Recruiting Phase 1 University of Miami · Miami, Florida · NCT06889493

• Inulin gel plus ipilimumab and nivolumab for advanced kidney (renal cell) cancer

  This trial tests whether adding an inulin gel to the immunotherapy drugs ipilimumab and nivolumab helps people with locally advanced or metastatic clear cell or sarcomatoid renal cell carcinoma.

  Recruiting Phase 1/2 University of Michigan Rogel Cancer Center · Ann Arbor, Michigan · NCT06866262

• Combining Niraparib and Ipilimumab for Metastatic Pancreatic Cancer Treatment

  This study is testing if combining two treatments, niraparib and ipilimumab, can help people with metastatic pancreatic cancer whose disease hasn't worsened after chemotherapy.

  Recruiting at 2 sites Phase 2 Abramson Cancer Center at Penn Medicine · Boston, Massachusetts and 1 other locations · NCT06747845

• Relatlimab, nivolumab, and ipilimumab for melanoma that has spread to the brain

  This trial will test whether the combination of relatlimab, nivolumab, and ipilimumab can help adults with melanoma brain metastases, including those with and without symptoms.

  Recruiting Phase 2 Stanford University · Palo Alto, California · NCT06712927

• Triplet combination of Relatlimab, Nivolumab, and Ipilimumab in first-line metastatic melanoma

  A first-line trial tests whether a three-drug combo can help people with metastatic melanoma, starting at a recommended dose.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT06683755

• Testing a new combination treatment for advanced melanoma

  This study is testing a new combination of three treatments for people with advanced melanoma that hasn't improved with other therapies to see if it can help them feel better.

  Recruiting at 12 sites Phase 2 Memorial Sloan Kettering Cancer Center · Los Angeles, California and 11 other locations · NCT06594991

• Investigating RP2 and Nivolumab for Metastatic Uveal Melanoma

  This study is testing whether a new treatment combining RP2 with nivolumab can help adults with metastatic uveal melanoma feel better compared to the standard treatment of nivolumab and ipilimumab.

  Recruiting at 33 sites Phase 2/3 Replimune, Inc. · Scottsdale, Arizona and 32 other locations · NCT06581406

• Combination treatment for liver metastases from uveal melanoma

  This study is testing a new combination treatment for patients with liver metastases from uveal melanoma to see if adding a special delivery method can help them live longer without their cancer getting worse.

  Recruiting at 3 sites Phase 3 Vastra Gotaland Region · Gothenburg and 5 other locations · NCT06519266

• Oral Alintegimod with Ipilimumab followed by Nivolumab for advanced cancer

  This study is testing if a new oral medication called Alintegimod, combined with two other cancer treatments, can help people with advanced solid tumors feel better and live longer.

  Recruiting at 4 sites Phase 1/2 7 Hills Pharma, LLC · Aurora, Colorado and 4 other locations · NCT06362369

• Local injection of ipilimumab and nivolumab for high-risk stage II melanoma

  This study is testing if injecting a combination of two immune-boosting drugs directly into the skin can help people with high-risk stage II melanoma by reducing the chance of cancer spreading.

  Recruiting at 2 sites Phase 1/2 The Netherlands Cancer Institute · Amsterdam and 5 other locations · NCT06240143

• Combining Naltrexone and Propranolol with Immunotherapy for Advanced Melanoma

  This study is testing if combining two medications, naltrexone and propranolol, with immune therapy can help people with advanced melanoma feel better and improve their treatment results.

  Recruiting Phase 1 Rutgers, The State University of New Jersey · New Brunswick, New Jersey · NCT05968690

• Combining immunotherapy with prednisone and sirolimus for kidney transplant recipients with advanced skin cancer

  This study is testing a new treatment that combines two immunotherapy drugs with prednisone and sirolimus to see if it helps kidney transplant recipients with advanced skin cancer while keeping their transplanted kidney safe.

  Recruiting at 25 sites Phase 1/2 National Cancer Institute (NCI) · La Jolla, California and 25 other locations · NCT05896839

• Combining axitinib with nivolumab for advanced kidney cancer treatment

  This study is testing if adding a drug called axitinib to nivolumab can help people with advanced kidney cancer see better results than just using nivolumab alone.

  Recruiting Phase 2 Consorzio Oncotech · Brescia and 22 other locations · NCT05817903

• Combining cryoablation with immunotherapy for advanced melanoma

  This study is testing if freezing tumors along with two immunotherapy drugs can help people with advanced melanoma that hasn't improved with other treatments.

  Recruiting Phase 2 Massachusetts General Hospital · Boston, Massachusetts · NCT05779423

• Stopping nivolumab early for melanoma treatment

  This study is testing if stopping nivolumab early is safe and effective for patients with advanced melanoma who have responded well to their initial treatment.

  Recruiting Erasmus Medical Center · Rotterdam · NCT05652673

• Combining CBL0137 with Ipilimumab and Nivolumab for Melanoma Treatment

  This study is testing a new drug called CBL0137 combined with standard melanoma treatments Ipilimumab and Nivolumab to see if it’s safe and helps people with advanced melanoma.

  Recruiting Early Phase 1 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT05498792

• Combining immunotherapy and chemoradiation for advanced cervical cancer

  This study is testing if adding two immunotherapy drugs to standard treatment can help people with advanced cervical cancer live longer without their disease getting worse.

  Recruiting at 6 sites Phase 2 Hospital Israelita Albert Einstein · Fortaleza, Ceará and 13 other locations · NCT05492123

• Combining Sarilumab with Other Treatments for Advanced Melanoma

  This study is testing a new combination of treatments for people with advanced melanoma to see if it helps them feel better and live longer.

  Recruiting at 4 sites Phase 2 NYU Langone Health · Los Angeles, California and 3 other locations · NCT05428007

• Combining axitinib and nivolumab for treating advanced mucosal melanoma

  This study is testing if a new combination of two cancer drugs, axitinib and nivolumab, can help people with advanced mucosal melanoma who haven't had treatment before feel better and live longer.

  Recruiting at 2 sites Phase 2 Memorial Sloan Kettering Cancer Center · Harrison, New York and 1 other locations · NCT05384496

• Combining nivolumab and ipilimumab for advanced colorectal cancer resistant to anti-PD1 treatment

  This study is testing if combining two cancer drugs, nivolumab and ipilimumab, can help people with advanced colorectal cancer that hasn't responded to other treatments.

  Recruiting at 9 sites Phase 2 GERCOR - Multidisciplinary Oncology Cooperative Group · Besançon and 8 other locations · NCT05310643

• Vaccine combined with immune therapy for advanced lung cancer

  This study is testing a new vaccine combined with immune therapy to see if it can help people with advanced lung cancer live longer and feel better.

  Recruiting Phase 1 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT05254184

• Testing nivolumab with or without ipilimumab for recurrent endometrial cancer

  This study is testing if adding ipilimumab to nivolumab can help people with recurrent endometrial cancer live longer and feel better compared to just using nivolumab alone.

  Recruiting at 122 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 137 other locations · NCT05112601

• Combining nivolumab, ipilimumab, and cabozantinib for untreated kidney cancer that has spread to the brain

  This trial tests whether adding the oral drug cabozantinib to two immunotherapy medicines (nivolumab and ipilimumab) helps people with untreated renal cell carcinoma brain metastases live longer or have their brain tumors shrink.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT05048212

• Neoadjuvant treatment for operable non-small cell lung cancer using low-dose radiation and immunotherapy

  This study is testing a new treatment combining low-dose radiation and immunotherapy for patients with early-stage non-small cell lung cancer to see if it helps shrink tumors before surgery.

  Recruiting Phase 2 Brown University · Providence, Rhode Island · NCT04933903

• Using telemonitoring to manage side effects in cancer patients receiving immunotherapy

  This study is testing if a telemonitoring system can help cancer patients receiving immunotherapy for melanoma, lung cancer, or renal cancer manage their side effects better by reporting their symptoms regularly.

  Recruiting at 3 sites Hospices Civils de Lyon · Bron and 9 other locations · NCT04605146

• Comparing two treatment combinations for melanoma with brain metastases

  This study is testing two different treatment combinations for patients with melanoma that has spread to the brain to see which one helps them live longer without the disease getting worse.

  Recruiting at 303 sites Phase 2 SWOG Cancer Research Network · Birmingham, Alabama and 330 other locations · NCT04511013

• Combining cabozantinib with ipilimumab/nivolumab and TACE for liver cancer treatment

  This study is testing if combining cabozantinib with two immune therapies and a specific type of chemo can help people with liver cancer who can’t have surgery feel better.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT04472767

• Vaccine treatment combined with immune therapy for a type of liver cancer

  This study is testing a new vaccine combined with immune therapy to see if it can help people with a specific type of liver cancer feel better and fight the disease.

  Recruiting Phase 1 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT04248569

• Combining immunotherapy and targeted therapy for rare bladder tumors

  This study is testing a new combination of treatments for people with rare bladder tumors that have spread, to see if it helps them live longer and feel better.

  Recruiting at 222 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 581 other locations · NCT03866382

• Nivolumab treatment for advanced basal cell carcinoma

  This study is testing if the drug nivolumab, alone or with other medications, can help people with advanced basal cell carcinoma that can't be removed by surgery.

  Recruiting Phase 2 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT03521830

• Combining immunotherapy and radiotherapy for melanoma brain metastases

  This study is testing if combining two immune therapies with targeted radiation can help people with melanoma that has spread to the brain feel better and live longer.

  Recruiting at 8 sites Phase 2 Melanoma Institute Australia · Sydney, New South Wales and 8 other locations · NCT03340129

• Combination treatment for advanced soft tissue sarcoma

  This study is testing a new combination of treatments using Trabectedin, Ipilimumab, and Nivolumab to see if it can help people with advanced soft tissue sarcoma who have already received other treatments.

  Recruiting Phase 1/2 Sarcoma Oncology Research Center, LLC · Santa Monica, California · NCT03138161

• Short-term immunotherapy for early-stage colon cancer

  This study is testing a new short-term immunotherapy treatment for early-stage colon cancer to see if it can help patients stay cancer-free after surgery.

  Recruiting at 4 sites Phase 2 The Netherlands Cancer Institute · Amsterdam and 5 other locations · NCT03026140

• Vaccine treatment for relapsed or refractory blood cancers

  This study is testing a new vaccine treatment for people with relapsed or hard-to-treat blood cancers to see if it can help them feel better and live longer.

  Recruiting at 2 sites Phase 1 Mayo Clinic · Scottsdale, Arizona and 1 other locations · NCT03017820

Quick answers

How many clinical trials of Ipilimumab are recruiting right now?

58, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 21 countries. The most sites are in United States (35 trials), China (9 trials), Australia (4 trials), Netherlands (3 trials), France (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 27, Phase 1: 12, Phase 1/2: 9, Phase 2/3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →